My take on RDHL updated-Target $25.00
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. They have three FDA approved gastrointestinal drugs: Movantik for opioid-induced constipation in adults, Talicia for Helicobacter pylori (H. pylori) infection in adults, and Aemcolo for travellers’ diarrhoea in adults.
RedHill has clinical late stage development pipeline which includes two Phase 2/3 programs in COVID-19 (opaganib and RHB-107), RHB-204 in a Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease, RHB-104 which successfully completed a first Phase 3 study for Crohn's disease, and RHB-102 which completed a Phase 3 study for acute gastroenteritis and gastritis and a Phase 2 study for IBS-D. IBS-D or "Irritable bowel syndrome with diarrhea" would be an extremely large unmet market. IBS-D is an untreated disability with many people suffering from it. Their commercial medications are held back due to Covid, yet company is involved in finding some remedy that may help eradicate or ease Covid symptoms.
Market Data 
Markets 
AI
